The pharmacokinetics of TNP-470, a new angiogenesis inhibitor

Pharmacotherapy

Volumn 17, Issue 1, 1997, Pages 91-97

  Figg, William D ^a   Pluda, James M ^a   Lush, Richard M ^a   Wayne Saville, M ^a   Wyvill, Kathy ^a   Reed, Eddie ^a   Yarchoan, Robert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGM 1883; ANGIOGENESIS INHIBITOR; DRUG METABOLITE; FUMAGILLOL CHLOROACETYLCARBAMATE; UNCLASSIFIED DRUG;

ADULT; ANGIOGENESIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; KAPOSI SARCOMA; MALE; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; CYCLOHEXANES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; SARCOMA, KAPOSI; SESQUITERPENES;

EID: 0031019609     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol 1992;3:89-96.
2. Sipos EP, Tamargo RJ, Weingart JD, Brem H. Inhibition of tumor angiogenesis. Ann NY Acad Sci 1994;732:263-72.
3. Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990;247:77-9.
4. Inoue K, Korenaga H, Tanaka N, Sakamoto N, Kadoya S. The sulfated polysaccharide-peptidoglycan complex potently inhibits embryonic angiogenesis and tumor growth in the presence of cortisone acetate. Carbohydr Res 1988;181:135-42.
5. Pluda JM, Shay LE, Foli A, et al. Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst 1993;85: 1585-92.
6. Nguyen NM, Lehr JE, Pienta KJ. Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo. Anticancer Res 1993;13:2143-7.
7. Takano S, Gately S, Neville ME, et al. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 1994;54:2654-60.
8. Hosang M. Suramin binds to PDGE and inhibits its biological activity. J Cell Biochem 1985;29:265-73.
9. Rastinejad F, Polverini PF, Bouck NP. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989;56:345-55.
10. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082-5.
11. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1990;348:555-7.
12. Kusaka M, Sudo K, Fujita T, et al. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun 1991;174:1070-6.
13. Safai B, Johnson KG, Myskowski PL, et al. The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 1985;103:744-50.
14. Saville MW, Lietzau J, Pluda JM, et al. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 1995;346:26-8.
15. Volberding PA, Abrams DI, Conant M, Kaslow K, Vranizan K, Ziegler J. Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 1985;103:335-8.
16. Gill PS, Rarick M, McCutchan JA, et al. Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. Am J Med 1991;90:427-33.
17. Krown SE, Real FX, Cunningham-Rundles S, et al. Preliminary observation on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med 1983;308:1071-6.
18. Nakamura S, Salahuddin SZ, Biberfeld P, et al. Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells. Science 1988;242:426-30.
19. Saville MW, Foli A, Broder S, Yarchoan R. In vitro activity of TNP-470, a novel angiogenesis inhibitor, in Kaposi's sarcoma (KS)-related spindle cells lines [abstr]. J Cell Biochem 1993;17E:22.
20. Saville MW, Foli A, Yarchoan R. Antiproliferative activity of TNP-470 (AGM-1470), a novel angiogenesis inhibitor, in Kaposi's sarcoma (KS)-related spindle cell lines [abstr]. Clin Res 1993;41:161A.
21. Pluda JM, Lietzau J, Wyvill K, et al. A phase I trial administering TNP-470 (AGM-1470) to patients with HIV-associated Kaposi's sarcoma [abstr]. Proceedings of the 1st National Conference on Human Retroviruses and Related Infections, 1993;1:61.
22. Pluda JM, Wyvill K, Figg WD, et al. A phase I study of an angiogenesis inhibitor, TNP-470 (AGM-1470), administered to patients with HIV-associated Kaposi's sarcoma [abstr]. Proc Am Soc Clin Oncol 1994;13:8.
23. Figg WD, Pluda JM, Wyvill K, et al. The pharmacokinetics of TNP-470, a new angiogenesis inhibitor [abstr]. Clin Res 1994;42:255.
24. Figg WD, Yeh HJC, Thibault A, et al. An assay of the antiangiogenic compound, TNP-470, and one of its metabolites, AGM-1883, by reversed-phase, high performance liquid chromatography in plasma. J Chromatogr 1994; 652:187-94.
25. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
26. Folkman J. Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med 1975;82:96-100.
27. Zukiwski A, Gutterman J, Bui C, et al. Phase I trial of the angiogenesis inhibitor TNP-470 (AGM-1470) in patients with androgen-independent prostate cancer [abstr]. Proc Am Soc Clin Oncol 1994;13:795.
28. Kato T, Sato K, Kakinuma H, Matsuda Y. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor o-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 1994;54:5143-7.
29. Abe J, Zhou W, Takuwa N, et al. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 1994;54:3407-12.
30. Kusaka M, Sudo K, Fujita T, et al. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophy Res Commun 1991;174:1070-6.
31. O'Reilly MS, Brem H, Folkman J. Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470. J Pediatr Surg 1995;30:325-9.
32. Cretton-Scott E, Placidi L, McClure H, Spandler M, Sommadossi JP. Pharmacokinetics of TNP-470, a potent angiogenesis inhibitor, in rhesus monkeys [abstr]. Proc Am Assoc Cancer Res 1995;36:2158.
33. Placidi L, Cretton-Scott E, DeSousa G, et al. Metabolic disposition of TNP-470 in primary cultured human hepatocytes [abstr]. Proc Am Assoc Cancer Res 1995;36:2159.
34. Ensoli B, Nakamura S, Salahuddin SZ, et al. AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 1989;243:223-6.